Literature DB >> 24091358

Nonalcoholic fatty liver disease: intravoxel incoherent motion diffusion-weighted MR imaging-an experimental study in a rabbit model.

Ijin Joo1, Jeong Min Lee, Jeong Hee Yoon, Ja Jun Jang, Joon Koo Han, Byung Ihn Choi.   

Abstract

PURPOSE: To evaluate the feasibility of using intravoxel incoherent motion (IVIM) diffusion-weighted imaging with multiple b values for the noninvasive diagnosis of nonalcoholic fatty liver disease (NAFLD).
MATERIALS AND METHODS: This study was approved by the institutional animal care and use committee. Twenty-seven 8-week-old rabbits were fed a variety of diets (from a standard diet to a high-fat, high-cholesterol diet) before IVIM diffusion-weighted imaging was performed with seven b values by using a 3-T magnetic resonance (MR) imaging unit. At histologic analysis of the animals, livers were categorized by NAFLD severity as normal, NAFLD, borderline nonalcoholic steatohepatitis (NASH), or NASH. The apparent diffusion coefficient and IVIM-derived parameters including true diffusion coefficient, pseudodiffusion coefficient, and perfusion fraction of the liver parenchyma were measured. Each parameter was correlated with NAFLD severity, and optimal cutoff values were determined by means of receiver operating characteristics analysis.
RESULTS: Perfusion fraction was significantly lower in rabbits with NAFLD than in those with a normal liver, and it decreased further as severity of NAFLD increased, with medians of 22.2%, 14.8%, 11.3%, and 9.5% in the rabbits in the normal, NAFLD, borderline, and NASH groups, respectively (ρ = -0.83, P < .001). Apparent diffusion coefficient, true diffusion coefficient, and pseudodiffusion coefficient were not significantly different between the NAFLD severity groups. In terms of the diagnostic performance of perfusion fraction, area under the curve values were 0.984 (normal vs NAFLD or more severe disease), 0.959 (NAFLD or less severe vs borderline or more severe disease), and 0.903 (borderline or less severe vs NASH) with optimal cutoff values of 15.2%, 13.2%, and 11.0%, respectively.
CONCLUSION: Perfusion fractions extracted from IVIM diffusion-weighted imaging may help in the differentiation of early stage NASH from simple steatosis. © RSNA, 2013.

Entities:  

Mesh:

Year:  2013        PMID: 24091358     DOI: 10.1148/radiol.13122506

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  24 in total

1.  Intravoxel Incoherent Motion-derived Histogram Metrics for Assessment of Response after Combined Chemotherapy and Radiation Therapy in Rectal Cancer: Initial Experience and Comparison between Single-Section and Volumetric Analyses.

Authors:  Stephanie Nougaret; Hebert Alberto Vargas; Yulia Lakhman; Romain Sudre; Richard K G Do; Frederic Bibeau; David Azria; Eric Assenat; Nicolas Molinari; Marie-Ange Pierredon; Philippe Rouanet; Boris Guiu
Journal:  Radiology       Date:  2016-02-26       Impact factor: 11.105

Review 2.  Liver intravoxel incoherent motion (IVIM) magnetic resonance imaging: a comprehensive review of published data on normal values and applications for fibrosis and tumor evaluation.

Authors:  Yáo T Li; Jean-Pierre Cercueil; Jing Yuan; Weitian Chen; Romaric Loffroy; Yì Xiáng J Wáng
Journal:  Quant Imaging Med Surg       Date:  2017-02

3.  Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function.

Authors:  Guobao Wang; Michael T Corwin; Kristin A Olson; Ramsey D Badawi; Souvik Sarkar
Journal:  Phys Med Biol       Date:  2018-07-24       Impact factor: 3.609

4.  Associations between histologic features of nonalcoholic fatty liver disease (NAFLD) and quantitative diffusion-weighted MRI measurements in adults.

Authors:  Paul Murphy; Jonathan Hooker; Brandon Ang; Tanya Wolfson; Anthony Gamst; Mark Bydder; Michael Middleton; Michael Peterson; Cynthia Behling; Rohit Loomba; Claude Sirlin
Journal:  J Magn Reson Imaging       Date:  2014-09-25       Impact factor: 4.813

Review 5.  Diffusion-weighted MRI of the liver: challenges and some solutions for the quantification of apparent diffusion coefficient and intravoxel incoherent motion.

Authors:  Yi Xiang J Wang; Hua Huang; Cun-Jing Zheng; Ben-Heng Xiao; Olivier Chevallier; Wei Wang
Journal:  Am J Nucl Med Mol Imaging       Date:  2021-04-15

Review 6.  CT and MR perfusion techniques to assess diffuse liver disease.

Authors:  Maxime Ronot; Benjamin Leporq; Bernard E Van Beers; Valérie Vilgrain
Journal:  Abdom Radiol (NY)       Date:  2020-11

Review 7.  Topics on quantitative liver magnetic resonance imaging.

Authors:  Yì Xiáng J Wáng; Xiaoqi Wang; Peng Wu; Yajie Wang; Weibo Chen; Huijun Chen; Jianqi Li
Journal:  Quant Imaging Med Surg       Date:  2019-11

8.  IVIM with fractional perfusion as a novel biomarker for detecting and grading intestinal fibrosis in Crohn's disease.

Authors:  Meng-Chen Zhang; Xue-Hua Li; Si-Yun Huang; Ren Mao; Zhuang-Nian Fang; Qing-Hua Cao; Zhong-Wei Zhang; Xu Yan; Min-Hu Chen; Zi-Ping Li; Can-Hui Sun; Shi-Ting Feng
Journal:  Eur Radiol       Date:  2018-12-13       Impact factor: 5.315

9.  Liver histology and diffusion-weighted MRI in children with nonalcoholic fatty liver disease: A MAGNET study.

Authors:  Paul Manning; Paul Murphy; Kang Wang; Jonathan Hooker; Tanya Wolfson; Michael S Middleton; Kimberly P Newton; Cynthia Behling; Hannah I Awai; Janis Durelle; Melissa N Paiz; Jorge E Angeles; Diana De La Pena; J Allen McCutchan; Jeffrey B Schwimmer; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2017-02-22       Impact factor: 4.813

10.  Apparent diffusion coefficient is highly reproducible on preclinical imaging systems: Evidence from a seven-center multivendor study.

Authors:  Sabrina Doblas; Gilberto S Almeida; François-Xavier Blé; Philippe Garteiser; Benjamin A Hoff; Dominick J O McIntyre; Lydia Wachsmuth; Thomas L Chenevert; Cornelius Faber; John R Griffiths; Andreas H Jacobs; David M Morris; James P B O'Connor; Simon P Robinson; Bernard E Van Beers; John C Waterton
Journal:  J Magn Reson Imaging       Date:  2015-05-26       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.